<DOC>
	<DOCNO>NCT03101566</DOCNO>
	<brief_summary>The purpose trial evaluate effect investigational drug nivolumab combination either gemcitabine/cisplatin chemotherapy , combination another investigational agent ipilimumab patient advance unresectable biliary tract cancer . Gemcitabine/cisplatin standard care treatment biliary tract cancer . Nivolumab ipilimumab type immunotherapy . Immunotherapy work encourage body 's immune system attack cancer cell . Nivolumab ( Opdivo ) FDA approve treatment several cancer include metastatic melanoma , advance lung , kidney , head &amp; neck bladder cancer . The combination nivolumab ipilimumab ( Yervoy ) FDA approve metastatic melanoma .</brief_summary>
	<brief_title>Study Nivolumab Combination With Gemcitabine/Cisplatin Ipilimumab Patients With Advanced Unresectable Biliary Tract Cancer</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must pathologically confirm adenocarcinoma biliary tract ( intrahepatic , extrahepatic ( hilar , distal ) gall bladder ) eligible curative resection , transplantation , ablative therapy . Patients may receive prior radiation , chemoembolization , radioembolization local ablative therapy hepatic resection complete ≥ 4 week prior registration AND patient recover &lt; = grade 1 toxicity . Patients must radiographically measurable disease least one site previously treat radiation liver direct therapy ( include bland , chemo radioembolization , ablation ) either within liver metastatic site . Age≥18 year ChildPugh score A ( prognosis chronic liver disease cirrhosis ) ECOG ( Eastern Cooperative Oncology Group ) performance status 01 Ability understand willingness sign IRBapproved inform consent Willing provide archive tissue , available , previous diagnostic biopsy Must able tolerate CT ( computerized tomography ) and/or MRI ( magnetic resonance imaging ) contrast Adequate organ function obtain ≤ 2 week prior registration Patients may receive prior systemic treatment ( chemotherapy target therapy ) advance BTC ( biliary tract cancer ) . Prior adjuvant chemotherapy permit provide complete &gt; 6 month registration . Must diagnosis immunodeficiency , receive systemic steroid therapy , form immunosuppressive therapy within 7 day prior trial treatment . No known Hepatitis B , Hepatitis C , HIV seropositivity . Testing required absence clinical suspicion . No prior history organ transplantation brain metastasis . Must undergone major surgical procedure &lt; 4 week prior registration . Must active second malignancy nonmelanoma skin cancer cervical carcinoma situ . Patients history malignancy eligible provide primary treatment cancer complete &gt; 1 year prior registration patient free clinical radiologic evidence recurrent progressive malignancy . Must ongoing active , uncontrolled infection Must receive live vaccine within 30 day plan start study therapy . Must psychiatric illness , significant medical illness , social situation , investigator 's opinion , would limit compliance ability comply study requirement . Women must pregnant breastfeed since nabpaclitaxel and/or gemcitabine may harm fetus child . Women childbearing potential men must agree use 2 method adequate contraception ( hormonal plus barrier 2 barrier form ) OR abstinence prior study entry , duration study participation 5 month ( woman ) 7 month ( men ) follow completion study therapy . Participants active , know suspected autoimmune disease . Participants type I diabetes mellitus , hypothyroidism require hormone replacement , skin disorder ( vitiligo , psoriasis , alopecia ) require systemic treatment , condition expect recur absence external trigger permit enroll . Participants condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day start study treatment . Inhaled topical steroid , adrenal replacement steroid dose &gt; 10 mg daily prednisone equivalent , permit absence active autoimmune disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>